# Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma

> **NCT00084617** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 39 (actual)

## Conditions studied

- Adenocarcinoma of the Gastroesophageal Junction
- Diffuse Adenocarcinoma of the Stomach
- Intestinal Adenocarcinoma of the Stomach
- Mixed Adenocarcinoma of the Stomach
- Recurrent Gastric Cancer
- Stage IIIA Gastric Cancer
- Stage IIIB Gastric Cancer
- Stage IIIC Gastric Cancer
- Stage IV Gastric Cancer

## Interventions

- **DRUG:** oxaliplatin
- **DRUG:** irinotecan hydrochloride
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT00084617
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2008-10
- **Final completion:** 2008-12
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2015-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00084617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00084617, "Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00084617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*